We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Shanghai-based Junshi Biosciences announced that it has finished enrolling participants in a phase 1 trial of JS016, its COVID-19 neutralizing antibody. Read More
More than 20 leading drugmakers have teamed up on a new program to develop innovative antibiotics in the coming decade to help curb the global threat of antibiotic-resistant infections. Read More
A new clinical trial network formed by the National Institute of Allergy and Infectious Diseases (NIAID) aims to accelerate COVID-19 vaccine research by using a standardized protocol to test multiple vaccine candidates, allowing results of the trials to be compared more easily. Read More
Merck and Eisai have received a complete response letter (CRL) from the FDA for Keytruda (pembrolizumab) plus Lenvima (lenvatinib) for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC). Read More
Chinese drugmaker Clover Biopharmaceuticals has received a $66 million investment from the Coalition for Epidemic Preparedness Innovations (CEPI) to support clinical development and manufacturing of its candidate COVID-19 vaccine. Read More